Bioniche Scientists Present at Modern Vaccine & Adjuvant Formulation Conference in France
a research-based, technology driven Canadian biopharmaceutical company,
today announced that two of its senior research scientists gave
presentations at the Modern Vaccine and Adjuvant Formulation Conference
in
Challenge Study Results for Econiche(TM)
Dr.
Sciences Inc., presented a paper that he co-authored, “Vaccination with
Type III Secreted Proteins Leads to Decreased Shedding in Calves
Following Experimental Infection with Escherichia coli O157″. The other authors were Dr.
Dr. Rogan’s presentation summarized the results of a study of the
Company’s E. coli O157 vaccine in an experimental infection (controlled challenge) model,
whereby thirty calves were immunized with the vaccine and commingled
with thirty calves that were administered a saline-adjuvant placebo.
Calves were vaccinated three times in a 42-day period, then were
infected with E. coli O157. Fecal shedding was monitored daily for 14 days. During this
period, vaccinates were shown to have a mean log shedding reduction of
1.4 (p=0.002). Researchers concluded that vaccination significantly reduced
the number of animals shedding E. coli O157, as well as the number of organisms shed. These data supported the
full licensure of the Company’s E. coli O157 vaccine (trademarked Econiche(TM)) by the Canadian Food Inspection Agency (CFIA), as announced in
October, 2008.
Immune Adjuvant Activity of Novel Oligonucleotide Sequences
Dr.
Chief Scientific Officer at Bioniche Life Sciences Inc., gave a
presentation about the Company’s oligonucleotide development program
and the latest oligonucleotide sequences that have been shown to have
immune adjuvant activity. His presentation was co-authored by Melanie
Lehoux and
Dr. Phillips highlighted the fact that these oligonucleotide sequences
contain non-DNA-bases and, unlike other oligonucleotide immune
adjuvants, do not require chemical modifications such as backbone
protection or terminal modification. The Company’s sequences have
demonstrated immune adjuvant activity in animal models using hepatitis
B surface antigen and H1N1 virions. These models have shown that they
are capable of inducing antiviral antibodies using very limited amounts
of antigen and short-term immunization protocols.
About the Oligonucleotide Technology Platform
In 2000, Bioniche announced the discovery of a new class of molecules
with potential anticancer activity, referred to by the Company under
the trademark, “Oligomodulator(TM)“. This new class of molecules with potential clinical anticancer
activity and immune modulating properties is composed of short
non-antisense DNA Oligonucleotides that appear to possess a range of
novel pharmacological activities. The Company has continued to develop
the Oligonucleotide technology platform in the areas of immune
stimulation and modulation.
About Econiche(TM)
Econiche(TM) has been developed by a strategic alliance formed in 2000 between the
(ARC), the
Organization (VIDO), and Bioniche, which holds the rights for worldwide
commercialization of the vaccine. The vaccine prevents the E. coli O157 bacteria from attaching to the intestines of vaccinated cattle,
thereby reducing their reproduction within the animal, and reducing the
amount of bacteria that can be released through cattle manure in the
environment. More than 30,000 cattle have been involved in clinical
testing of the vaccine, which is fully licensed in
conditional license is pending.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary products for
human and animal health markets worldwide. The fully-integrated company
employs approximately 211 skilled personnel and has three operating
divisions: Human Health, Animal Health, and Food Safety. The Company’s
primary goal is to develop proprietary cancer therapies supported by
revenues from marketed products in human and animal health. For more
information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company’s current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company’s ongoing quarterly and
annual reporting.
SOURCE Bioniche Life Sciences Inc.